Methods
ADVANCED CANCER
MedCan-1 (ANZCTR 26180001220257) was designed to determine whether CBD oil reduced total symptom burden in patients with advanced cancer to a greater extent than placebo and has been published previously [Participants provided written fully informed consent for both the parent and sub-study. Approval was obtained from the Mater Human Research Ethics Committee.